Finerenone improves ambulatory blood pressure in chronic kidney disease

Finerenone reduces 24-h, daytime, and night-time systolic blood pressure in patients with chronic kidney disease and type 2 diabetes, says a latest study published in the Journal of Hypertension.

This phase 2b trial assessed the effects of finerenone on 24-h ambulatory BP in 823 patients with type 2 diabetes and chronic kidney disease. The study included patients with albumin-to-creatinine ratio ≥30 mg/g and estimated glomerular filtration rate of 30-90 ml/min per 1.73 m2. The participants were randomized to receive wither finerenone (1.25-20 mg once daily in the morning) administered over 90 days or placebo. Ambulatory BP monitoring (ABPM) over 24 h was performed in a subset of 240 patients at screening, Day 60, and Day 90.

At Day 90, the 24-h ABPM systolic BP (SBP) was -8.3 mmHg for finerenone 10 mg (n = 27), -11.2 mmHg for finerenone 15 mg (n = 34), and -9.9 mmHg for finerenone 20 mg (n = 31). Mean daytime and night-time SBP recordings were similarly reduced and finerenone did not increase the incidence of SBP dipping.

According to the results, finerenone can reduce 24-h, daytime, and night-time SBP and these changes in the BP can be persistent over 24 h with once-daily dosing in the morning.